Orphazyme: Competitor fails in NPC
Mallinckrodt has announced that their VTS-270 project, a competitor to Orphazyme's arimoclomol for the treatment of NPC, failed to show statistically significant efficacy in their Phase II/III trial. No details has been released around the data.